Who are Volbella or Juvederm Ultra XC filler's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/volbella-or-juvederm-ultra-xc-filler.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Volbella or Juvederm Ultra XC filler — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Volbella or Juvederm Ultra XC filler (Volbella or Juvederm Ultra XC filler) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hyaluronic acid filler. Area: Dermatology.

phase 3 Hyaluronic acid filler Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Volbella or Juvederm Ultra XC filler (Volbella or Juvederm Ultra XC filler) — DeNova Research. Volbella or Juvederm Ultra XC filler works by providing temporary volume and structure to the skin through hyaluronic acid gel.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Volbella or Juvederm Ultra XC filler TARGET	Volbella or Juvederm Ultra XC filler	DeNova Research	phase 3	Hyaluronic acid filler

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hyaluronic acid filler class)

DeNova Research · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Volbella or Juvederm Ultra XC filler — Competitive Intelligence Brief. https://druglandscape.com/ci/volbella-or-juvederm-ultra-xc-filler. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab